References
- Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. In: Goodin DS, editor. Handbook of clinical neurology, multiple sclerosis and related disorders. Vol. 122. New York (NY): Elsevier; 2014. p. 15–58.
- Michel L, Larochelle C, Prat A. Update on treatments in multiple sclerosis. Press Med. 2015;44:137–151.
- Aharoni R. New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis. Expert Rev Clin Immunol. 2013;9:423–440.
- Bhatt A, Fan LW, Pang Y. Strategies for myelin regeneration: lessons learned from development. Neural Regen Res. 2014;9:1347–1350.
- Simons M, Nave KA. Oligodendrocytes: myelination and axonal support. In: Barres BA, Freeman MR, Stevens B, editors. Cold spring harbor perspective in biology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015. p. 1–15.
- Aharoni R, Arnon R. Linkage between immunomodulation neuroprotection and neurogenesis. Drug News Perspect. 2009;22:301–312.
- Hanafy KA, Sloane JA. Regulation of remyelination in multiple sclerosis. FEBS Lett. 2011;585:3821–3828.
- Luessi F, Siffrin V, Zipp F. Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev Neurother. 2012;12:1061–1076.
- Aharoni R, Herschkovitz A, Eilam R, et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008;105:11358–11363.
- Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE affected by glatiramer acetate. J Neural Transm. 2009;116:1443–1449.
- Aharoni R, Vainshtein A, Stock A, et al. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J Autoimmun. 2011;37:228–241.
- Aharoni R, Sasson E, Blumenfeld T. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate. Exp Nerurol. 2013;240:130–144.
- From R, Eilam R, Bar-Lev DD, et al. Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate. GLIA. 2014;62:549–665.
- Aharoni R, Eilam R, Domev H, et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalo-myelitis in mice. Proc Natl Acad Sci USA. 2005;102:19045–19050.
- Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010;176:2682–2694.
- Alme MN, Nystad AE, Bø L, et al. Fingolimod does not enhance cerebellar remyelination in the cuprizone model. J Neuroimmunol. 2015;15:180–186.
- Aharoni R, Saada R, Eilam R, et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;251:14–24.
- Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27:493–503.
- Chesik D, Wilczak N, De Keyser J. The insulin-like growth factor system in multiple sclerosis. Int Rev Neurobiol. 2007;79:203–226.
- Woodbury ME, Ikezu TJ. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. Neuroimmunol Pharmacol. 2014;9:92–101.
- Kremer D, Küry P, Dutta R. Promoting remyelination in multiple sclerosis: current drugs and future prospects. Mult Scler J. 2015;21:541–549.
- Olsen JA, Akirav EM. Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches. J Neurosci Res. 2015;93:687–696.
- Orack JC, Deleidi M, Pitt D, et al. Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. Stem Cells Transl Med. 2015;4:252–260.